Get the Stockscreener App
53.04
0.34%
0.18
After Hours:
52.66
-0.38
-0.72%
Gsk Plc Adr stock is traded at $53.04, with a volume of 3.81M.
It is up +0.34% in the last 24 hours and up +4.20% over the past month.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
See More
Previous Close:
$52.86
Open:
$53.13
24h Volume:
3.81M
Relative Volume:
0.93
Market Cap:
$106.31B
Revenue:
$43.93B
Net Income/Loss:
$8.53B
P/E Ratio:
13.87
EPS:
3.824
Net Cash Flow:
$5.74B
1W Performance:
+2.95%
1M Performance:
+4.20%
6M Performance:
+8.67%
1Y Performance:
+24.83%
1-Day Range:
$52.89
$53.45
1-Week Range:
$50.35
$53.45
52-Week Range:
$35.45
$61.70
Gsk Plc Adr Stock (GSK) Company Profile
Name
Gsk Plc Adr
Sector
Industry
Phone
-
Address
-
Compare GSK vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
53.04 | 106.31B | 43.93B | 8.53B | 5.74B | 3.824 |
LLY
Lilly Eli Co
|
1,133.00 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
240.87 | 579.83B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
227.73 | 402.35B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
119.05 | 294.03B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.07 | 292.07B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Neutral |
| Jan-06-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Nov-25-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-03-25 | Downgrade | Berenberg | Buy → Hold |
| Apr-15-25 | Initiated | Exane BNP Paribas | Neutral |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-15-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Nov-12-24 | Downgrade | Jefferies | Buy → Hold |
| Oct-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-24 | Downgrade | UBS | Buy → Neutral |
| May-30-24 | Initiated | Goldman | Neutral |
| Mar-04-24 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-13-24 | Upgrade | Citigroup | Neutral → Buy |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Jan-03-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Mar-17-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-27-23 | Resumed | Goldman | Buy |
| Jan-03-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-11-22 | Downgrade | UBS | Neutral → Sell |
| Sep-15-22 | Upgrade | Credit Suisse | Underperform → Neutral |
| Sep-08-22 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-21-22 | Resumed | Citigroup | Neutral |
| Feb-11-22 | Downgrade | DZ Bank | Buy → Hold |
| Nov-05-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Jun-24-21 | Upgrade | Deutsche Bank | Sell → Hold |
| Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-04-21 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-20-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jan-15-21 | Initiated | Deutsche Bank | Hold |
| Nov-02-20 | Upgrade | Liberum | Hold → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Feb-12-20 | Downgrade | Shore Capital | Hold → Sell |
| Jan-16-20 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-19 | Initiated | SVB Leerink | Outperform |
| Nov-21-19 | Upgrade | UBS | Neutral → Buy |
| Oct-11-19 | Upgrade | Cantor Fitzgerald | Hold → Buy |
| Sep-03-19 | Resumed | Citigroup | Neutral |
| Sep-03-19 | Upgrade | Societe Generale | Sell → Buy |
| Aug-13-19 | Resumed | JP Morgan | Neutral |
| Jun-17-19 | Resumed | Morgan Stanley | Underweight |
| Mar-08-19 | Downgrade | Shore Capital | Buy → Hold |
| Feb-22-19 | Downgrade | UBS | Buy → Neutral |
| Jan-14-19 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Dec-11-18 | Resumed | Jefferies | Buy |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Aug-30-18 | Downgrade | Liberum | Buy → Hold |
| Apr-04-18 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-22-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-09-18 | Upgrade | Kepler | Reduce → Hold |
View All
Gsk Plc Adr Stock (GSK) Latest News
GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder - TradingView
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion - Investing.com
GSK Stock Quote Price and Forecast - CNN
GSK plc stock (GB0009252882): Nuvalent deal sharpens oncology focus - AD HOC NEWS
GSK to strengthen oncology pipeline with $10.6B Nuvalent buyout - MSN
GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout - TradingView
GSK to acquire cancer biotech Nuvalent in $10.6 billion deal - grafa.com
UPDATE 4-GSK boosts cancer portfolio with $10.6 billion Nuvalent takeover - Sahm
Why is Glaxo (GSK) down 2.1% since last earnings report? - MSN
GSK Bets on Specialty Medicines to Drive Long-Term Revenue Growth - TradingView
GSK Stock Price, Quote & Chart | GSK PLC-SPON ADR (NYSE:GSK) - ChartMill
GSK plc (ADR) stock (GB0009252882): ADR treads water around mid-USD 50s as London shares retreat on - AD HOC NEWS
GSK plc (ADR) stock (GB0009252882): ADR holds steady as investors await next catalysts after recent - AD HOC NEWS
GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs Revenue Breakdown – BCBA:GSK.CI - TradingView
GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs Earnings and Revenue – BCBA:GSK.CI - TradingView
GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs Balance Sheet – BCBA:GSK.CI - TradingView
GSK PLC-SPON ADR (NYSE:GSK) Passes Quality-Focused Caviar Cruise Stock Screener with Strong Profitability and Cash Flow - ChartMill
GSK plc stock (GB0009252882): buyback activity and Q1 update keep focus on vaccines and specialty me - AD HOC NEWS
GSK PLC (GSK) Stock Price, Trades & News - GuruFocus
GSK plc stock (GB0009252882): asthma drug progress and Q1 update draw investor focus - AD HOC NEWS
GSK plc stock (GB0009252882): Q1 2026 beat, raised outlook and steady dividend attract fresh attenti - AD HOC NEWS
GSK plc stock (GB0009252882): Fresh 13F filing and annual report keep big pharma in focus - AD HOC NEWS
25 New 4-Star Stocks This Week - Morningstar
GSK plc (GSK) Stock Price, News, Quote & History - Yahoo Finance
GSK plc stock (GB0009252882): Mixed signals from recent earnings and pipeline updates - AD HOC NEWS
Gsk Plc Adr Stock (GSK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):